A study from Zambia has found that a programme of couples
voluntary counselling and testing (CVCT), in which male/female couples are counselled
together before testing for HIV and again after testing, was more effective in
itself in reducing transmission within couples than the
partner living with HIV starting antiretroviral therapy (ART) without any element of couples work.
The study also found that CVCT greatly enhanced the preventive effect of antiretroviral treatment, when compared to treatment without counselling, in an analysis of a large cohort of couples who had counselling and testing together.
“Counselling is essential for treatment as prevention to work
in Africa”, presenter Kristin Wall from Emory University in Atlanta, Georgia,
told the 20th International AIDS Conference (AIDS 2014).
CVCT is a specific support paradigm supported by the US
funding programme PEPFAR and the US Centers for Disease Control and Prevention (CDC), in which
heterosexual couples are counselled together when considering an HIV test, take
the test together, and are counselled together on the implications of the
result, whatever it is, afterwards.
As the CDC
website explains, the object of counselling couples rather than individuals
is to mitigate tension, diffuse blame, and create an environment in which
disclosure of status can be accomplished safely in populations in which it is
often associated with relationship break-up and violence.
A programme of CVCT was started in Lusaka, Zambia in 2007 and
was progressively scaled up to two more provinces in 2010 and 2011. So far, over
150,000 couples have received CVCT. Of these, 74% (about 114,000) were both HIV negative when
first tested: 14% (22,000) were both HIV positive: and 12% were of different HIV status
(in 7% of couples the woman was the HIV-positive partner (10,263 women) and in 5%, the man (7710 men)).
Previous surveillance in Zambia had shown that in couples of
differing HIV status, annual HIV incidence in the HIV-negative partner was 11%
(i.e. one in nine acquired HIV per year). In couples where both were HIV
negative, incidence – i.e. the introduction of HIV into the couple from an outside
partner – was 1.4% a year.
Repeated HIV testing established that after having CVCT,
HIV incidence in couples of differing HIV status declined to 2% a year (i.e. one
in 50 of the HIV-negative partners acquired HIV a year). This represents an 82%
decline in incidence. Similarly, in couples where both were HIV negative, the acquisition
rate of HIV from outside the relationship declined to 0.44% a year, a 69%
reduction in incidence.
CVCT was clearly effective in itself in helping people avoid
HIV, and the researchers calculated that it was highly cost-effective: the cost
of averting one HIV infection in Zambia with CVCT was US$392.
In the couples with differing HIV status, 21% of the
partners living with HIV were already taking antiretroviral therapy (ART – often without
their partner’s knowledge: one thing the CVCT programme did was help people living with HIV to disclose a status they may have been concealing for some time). This
meant that the fall in incidence seen in the HIV-negative partners was a combination
of the effects of CVCT and of ART reducing the HIV-positive partner’s
The researchers teased apart the contributions of CVCT and of
ART by looking at HIV incidence in the 12% of serodiscordant couples who had CVCT but where the partner living with HIV did not start ART, and
comparing it with couples where the partner living with HIV had been on ART prior
to CVCT and recording incidence in the HIV-negative partners prior to CVCT.
In couples who had received CVCT but where the
partner living with HIV did not start ART, the reduction in incidence in the HIV-negative partners
was 70%. In contrast, the reduction in incidence in couples where the partner living with HIV started ART prior to receiving CVCT (comparing pre- and post-ART
incidence) was only 30% – far lower than that recorded in efficacy trials of
couples like HPTN 052, and considerably lower than the efficacy of CVCT alone.
Where ART in the partner living with HIV and CVCT were combined, the
reduction in incidence in the HIV-negative partners was 83%. This means that in
couples where the partner living with HIV was on ART, the additional cost per
infection avoided of the CVCT was US$666. However, receiving CVCT also seemed to increase
the efficacy of the ART component of this combined prevention effect: previous studies
of CVCT had shown that in couples that received CVCT, if the partner living with HIV started ART then this further reduced the chance of HIV transmission to the HIV-negative partner by 60%.
What were the drivers of this counter-intuitive result, given
that randomised controlled trials of both ART and of counselling and
support have shown the former to be far superior in terms of efficacy?
One key factor is that adherence in the ‘real-life’ setting of
Zambia is very poor. One survey quoted by presenter Kristin Wall found that
only 60% of people taking ART in Zambia were adequately adherent and that, in
addition to this, 25% dropped out of care per year. There may be some contribution from drug
resistance too: currently 5 to 6% of people living with HIV in Zambia who are drug-naive (have never taken HIV treatment) have
A number of studies have teased apart the contributors to poor adherence
in Zambia. Ones that appear consistently are food insecurity, long distances to
clinic, poor information about treatment, and some faith practices.
The most consistent predictor of poor adherence, however, said
Wall, was lack of disclosure between couples. Adherence was very poor in people
who had not disclosed that they had HIV to their partner, especially as
disclosure often involved relationship break-up and, very often for women living with HIV, violence. In 44% of the transmissions observed in serodiscordant
couples, the partner living with HIV had supposedly been on ART.
“Couple counselling should be a priority in ART clinics in
Africa,” Wall said. “Our research showed that it greatly increases the prevention
effectiveness and cost-effectiveness of HIV treatment.”